Willow Biosciences completes first commercial-scale fermentation run of ultra-pure CBG

Willow Biosciences Inc (TSE:WLLW) (OTCQX:CANSF) (FRA:3D7) has completed the first commercial scale fermentation run of cannabigerol, or CBG, it announced Wednesday.  The news comes after Willow had already executed successful pilot production runs to optimize its process and provide samples of CBG to customers.  Vancouver-based Willow is pioneering a process to develop and produce high-purity, plant-derived cannabidiols for consumer-packaged goods and pharmaceutical industries.  READ: Willow Biosciences on track to commercialize ultra-pure cannabinoids in 2021 with over C$47M in the bank Production from its first commercial fermentation run is being allocated for sale to prospective customers, according to Willow. The company is in the process of finalizing agreements with multiple parties, it added.  In a statement Wednesday, CEO Trevor Peters told investors that the company was very pleased with the yield and quality of its first commercial-scale fermentation run of CBG. "I think it is important to take a moment to reflect on all that we have achieved in just under two years as a public company,” Peters said. “In this time, we built a world class industrial R&D team, demonstrated proof of concept for production of cannabinoids through fermentation, attracted reputable development partners like Albany Molecular Research Inc, and produced our first commercial scale batch of CBG. “On the capital markets side, we have completed three successful financings, bringing in supportive and sophisticated shareholders who have provided us with a healthy balance sheet to execute on our business plan. We are now starting the next phase of Willow's lifecycle, which will involve supplying commercial quantities of cannabinoids to customers and recognizing revenue therefrom." Cosmetic applications The company is also working with Signum Biosciences Inc, a leading biopharmaceutical company focused on the discovery and development of innovative consumer products, to test the safety and efficacy of Willow's CBG in cosmetics. According to a statement, preliminary data indicates that Willow's CBG is safe and can act as a potent antioxidant, anti-inflammatory and antibacterial in skin applications. Willow said it will continue production with its CMO throughout 2021 to meet anticipated demand of its ultra-pure CBG. Contact Angela at angela@proactiveinvestors.com Follow her on Twitter @AHarmantas